Mizuho Reiterates Buy on BridgeBio Pharma, Maintains $60 Price Target
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Salim Syed has reiterated a 'Buy' rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $60.
August 28, 2023 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Salim Syed has reiterated a 'Buy' rating on BridgeBio Pharma and maintained a price target of $60.
The 'Buy' rating from Mizuho indicates a positive outlook for BridgeBio Pharma. The maintained price target of $60 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100